Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma / Strauss SJ; Morschhauser F; Rech J; Repp R; Solal-Celigny P; Zinzani PL; Engert A; Coiffier B; Hoelzer DF; Wegener WA; Teoh NK; Goldenberg DM; Lister TA.. - In: JOURNAL OF CLINICAL ONCOLOGY. - ISSN 0732-183X. - STAMPA. - 24:(2006), pp. 3880-3886. [10.1200/JCO.2006.05.6291]
Multicenter phase II trial of immunotherapy with the humanized anti-CD22 antibody, epratuzumab, in combination with rituximab, in refractory or recurrent non-Hodgkin's lymphoma.
ZINZANI, PIER LUIGI;
2006
File in questo prodotto:
Eventuali allegati, non sono esposti
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.